J&J Expands Availability of Tecnis Odyssey PC-IOL
Johnson & Johnson announced the expansion of its Tecnis Odyssey presbyopia-correcting IOL (PC-IOL) across the US. The Tecnis Odyssey IOL offers patients continuous full-range vision, reducing the need for glasses by providing clear vision from far to near and everything in between[3,6]. Built on the Tecnis platform, the Odyssey delivers 2 times better contrast in low-light conditions compared to PanOptix, along with improved ability to read smaller print and fewer visual disturbances like halos or glare[7,8], according to J&J.
“More than 14,000 eyes have already benefited from TECNIS Odyssey, our new full visual range IOL. The feedback from patients has been overwhelmingly positive, and we’re thrilled to expand its availability across the US,” Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson, said in a company news release. “Cataract surgery provides patients a unique opportunity to restore and enhance their vision, and with Tecnis Odyssey, they can enjoy sharp, clear sight at every distance without relying on glasses.”
The Tecnis Odyssey IOL employs proprietary technology to deliver superior image quality, even in low-light environments. Its freeform diffractive surface is engineered for continuous, uninterrupted vision across near, intermediate, and far distances, ensuring patients can see clearly for all daily activities, from reading to driving.[7,8,12]
Key outcomes[13,14] from Tecnis Odyssey clinical trials include:
- 94% of patients were satisfied with their overall vision without glasses
- 96% of patients were satisfied with their ability to read smartphones or tablets
- 92% of patients reported being able to see steps and read street signs clearly at night
In addition to the US expansion, the Tecnis Odyssey IOL has received regulatory approval in Japan, the EU, Korea, Canada, Singapore, Australia, and New Zealand. To support this rollout, Johnson & Johnson is launching "Tecnis Odyssey IOL Peer Connect," an interactive platform aimed at fostering direct communication between healthcare professionals and expert surgeons who have used the lens.
For more information on Tecnis Odyssey IOL and patient tools, visit www.clearvisionforyou.com. Healthcare professionals can access additional resources and request more information at TECNISOdysseyIOL.com.
References
1 Data on File. 2024DOF4002
2 Data on File. DOF2023CT4049
3 Data on File. DOF2023CT4056
4 Data on File. DOF2023CT4051
5 Data on File. 2024DOF4003
6 Data on File. DOF2023CT4023
7 Data on File. DOF2019OTH4002
8 Data on File. DOF2023CT4007
9 Data on File. DOF2023CT4050
10 CDC About Common Eye Disorders & Diseases (2024). Access from: https://www.cdc.gov/vision-health/about-eye-disorders/
11 American Academy of Ophthalmology (2024) Access from: https://www.aao.org/eye-health/diseases/what-is-presbyopia
12 Data on File. 2024DOF4005
13 Data on File. 2024DOF4027
14 Data on File. 2024DOF4029
15 DFU for TECNIS Odyssey IOL; Data on File 2024DOF4030 (comparison of binocular, mesopic contrast sensitivity without-glare results from two bilateral implantation studies: 3-month post-op, ambispective, multicenter, observational clinical study of (n= 27) TECNIS Odyssey IOL and a 1-month post-op, prospective, multicenter, randomized, double-masked clinical study of (n=135) the parent IOL and (n=137) TECNIS Monofocal IOL)